DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.04+0.43 (+0.53%)
Close on Nov 17, 2026Market cap $30.60BP/E 32.3Yield –
DexCom cash
Cash and short-term investments held at the end of each period.
DexCom's cash was $961.40M at Sep 30, 2026. For fiscal 2025 it was $917.70M, down 60.7% from the year before. Over ten years it grew 23.1% a year on average. The highest annual figure on record is $2.73B in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $917.70M | -60.7% |
| FY2024 | Dec 31, 2024 | $2.34B | -14.3% |
| FY2023 | Dec 31, 2023 | $2.73B | +11.1% |
| FY2022 | Dec 31, 2022 | $2.45B | +1.6% |
| FY2021 | Dec 31, 2021 | $2.41B | +195.0% |
| FY2020 | Dec 31, 2020 | $818.20M | +83.3% |
| FY2019 | Dec 31, 2019 | $446.40M | -63.7% |
| FY2018 | Dec 31, 2018 | $1.23B | +124.2% |
| FY2017 | Dec 31, 2017 | $548.60M | +343.5% |
| FY2016 | Dec 31, 2016 | $123.70M | +7.4% |
| FY2015 | Dec 31, 2015 | $115.20M | +37.8% |
| FY2014 | Dec 31, 2014 | $83.60M | +53.1% |
| FY2013 | Dec 31, 2013 | $54.60M | +12.1% |
| FY2012 | Dec 31, 2012 | $48.70M | -40.5% |
| FY2011 | Dec 31, 2011 | $81.90M | +73.8% |
| FY2010 | Dec 31, 2010 | $47.12M | +1209.0% |
| FY2009 | Dec 31, 2009 | $3.60M | -71.7% |
| FY2008 | Dec 31, 2008 | $12.70M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $961.40M | -47.6% |
| Q2 FY2026 | Jun 30, 2026 | $1.11B | -4.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.12B | -54.6% |
| Q4 FY2025 | Dec 31, 2025 | $917.70M | -60.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.84B | -19.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.16B | -61.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.46B | -6.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.34B | -14.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.27B | -30.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.97B | -18.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.62B | +2.3% |
| Q4 FY2023 | Dec 31, 2023 | $2.73B | +11.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.24B | +37.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.63B | +31.9% |
| Q1 FY2023 | Mar 31, 2023 | $2.56B | -1.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.45B | +1.6% |
| Q3 FY2022 | Sep 30, 2022 | $2.37B | -6.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.75B | +137.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.59B | +252.8% |
| Q4 FY2021 | Dec 31, 2021 | $2.41B | +195.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.53B | +275.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.16B | +118.6% |
| Q1 FY2021 | Mar 31, 2021 | $733.80M | +25.5% |
| Q4 FY2020 | Dec 31, 2020 | $818.20M | +83.3% |
| Q3 FY2020 | Sep 30, 2020 | $673.50M | +70.2% |
| Q2 FY2020 | Jun 30, 2020 | $530.00M | -25.3% |
| Q1 FY2020 | Mar 31, 2020 | $584.60M | -54.5% |
| Q4 FY2019 | Dec 31, 2019 | $446.40M | -63.7% |
| Q3 FY2019 | Sep 30, 2019 | $395.60M | -40.8% |
| Q2 FY2019 | Jun 30, 2019 | $709.20M | +17.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.29B | +140.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.23B | +124.2% |
| Q3 FY2018 | Sep 30, 2018 | $668.70M | +27.2% |
| Q2 FY2018 | Jun 30, 2018 | $606.10M | +22.0% |
| Q1 FY2018 | Mar 31, 2018 | $533.90M | +194.8% |
| Q4 FY2017 | Dec 31, 2017 | $548.60M | +343.5% |
| Q3 FY2017 | Sep 30, 2017 | $525.80M | – |
| Q2 FY2017 | Jun 30, 2017 | $496.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $181.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $123.70M | – |
See a number that looks wrong?